TO THE EDITOR:

Tyrosine kinase inhibitors (TKIs) are used post-allogeneic hematopoietic cell transplantation (HCT) to reduce relapse rates in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).1,2  However, because results from retrospective studies are conflicting2-9  and there has been no definitive randomized trial,10  the role and duration of maintenance therapy with TKIs post-transplant remain uncertain. Herein, we present updated outcomes of patients with Ph+ ALL who received HCT followed by TKI maintenance at our institution11  and evaluate the impact of TKIs (including newer generations) on survival outcomes in light of available measurable residual disease (MRD), as assessed by quantitative polymerase chain reaction for BCR-ABL1 transcripts at the time of HCT. Furthermore, we attempt to identify the optimal duration of TKI therapy after transplantation.

A total of 171 patients with Ph+ ALL consecutively underwent first HCT...

REFERENCES

REFERENCES
1.
Abou Dalle
I
,
Jabbour
E
,
Short
NJ
,
Ravandi
F
.
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
.
Curr Treat Options Oncol
.
2019
;
20
(
1
):
4
.
2.
Warraich
Z
,
Tenneti
P
,
Thai
T
, et al
.
Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review
.
Biol Blood Marrow Transplant
.
2020
;
26
(
3
):
e55
-
e64
.
3.
Giebel
S
,
Czyz
A
,
Ottmann
O
, et al
.
Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
.
Cancer
.
2016
;
122
(
19
):
2941
-
2951
.
4.
Litzow
MR
.
Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: is it imperative in the tyrosine kinase inhibitor era?
Best Pract Res Clin Haematol
.
2018
;
31
(
4
):
357
-
360
.
5.
Carpenter
PA
,
Snyder
DS
,
Flowers
MED
, et al
.
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
.
Blood
.
2007
;
109
(
7
):
2791
-
2793
.
6.
Akahoshi
Y
,
Nishiwaki
S
,
Mizuta
S
, et al;
Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
.
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia
.
Cancer Sci
.
2019
;
110
(
10
):
3255
-
3266
.
7.
Chen
H
,
Liu
K-Y
,
Xu
L-P
, et al
.
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
.
J Hematol Oncol
.
2012
;
5
:
29
.
8.
Brissot
E
,
Labopin
M
,
Beckers
MM
, et al
.
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
.
Haematologica
.
2015
;
100
(
3
):
392
-
399
.
9.
Zhang
FH
,
Ling
YW
,
Zhai
X
, et al
.
The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
.
Hematology
.
2013
;
18
(
3
):
151
-
157
.
10.
Pfeifer
H
,
Wassmann
B
,
Bethge
W
, et al;
GMALL Study Group
.
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
.
Leukemia
.
2013
;
27
(
6
):
1254
-
1262
.
11.
Kebriaei
P
,
Saliba
R
,
Rondon
G
, et al
.
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes
.
Biol Blood Marrow Transplant
.
2012
;
18
(
4
):
584
-
592
.
12.
Short
NJ
,
Jabbour
E
,
Sasaki
K
, et al
.
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
.
Blood
.
2016
;
128
(
4
):
504
-
507
.
13.
Soverini
S
,
Vitale
A
,
Poerio
A
, et al
.
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
.
Haematologica
.
2011
;
96
(
4
):
552
-
557
.
14.
Soverini
S
,
De Benedittis
C
,
Papayannidis
C
, et al
.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement
.
Cancer
.
2014
;
120
(
7
):
1002
-
1009
.
You do not currently have access to this content.